K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Journal ArticleDOI
Biology and clinical relevance of EpCAM.
TL;DR: The current knowledge on the biological properties of EpCAM is summarized with emphasis on mechanisms involved in cancer progression and the clinical implications of these findings for the clinical use ofEpCAM as a diagnostic marker are discussed.
Journal ArticleDOI
Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells
Tobias M. Gorges,Andra Kuske,Katharina Röck,Oliver Mauermann,Volkmar Müller,Sven Peine,Karl Verpoort,Vendula Novosadova,Mikael Kubista,Sabine Riethdorf,Klaus Pantel +10 more
TL;DR: Multimarker RNA profiling of single CTCs reveals distinct CTC subsets and provides important insights into gene regulatory networks relevant for cancer progression and therapy.
Journal ArticleDOI
Dual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer
Stefan Werner,Sabrina Frey,Sabine Riethdorf,Christian Schulze,Malik Alawi,Lea Kling,Vida Vafaizadeh,Guido Sauter,Luigi Terracciano,Udo Schumacher,Klaus Pantel,Volker Assmann +11 more
TL;DR: Interestingly, expression of GRHL2 is directly suppressed by the transcription factor zinc finger enhancer-binding protein 1 (ZEB1), suggesting that the EMT transcription factors GRHL 2 and ZEB1 form a double negative regulatory feedback loop in breast cancer cells.
Journal ArticleDOI
Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral Cavity
Alexander Gröbe,Marco Blessmann,Henning Hanken,Reinhard E Friedrich,Gerhard Schön,Johannes Wikner,Katharina E. Effenberger,Lan Kluwe,Max Heiland,Klaus Pantel,Sabine Riethdorf +10 more
TL;DR: Both DTCs and CTCs are independent prognostic markers in patients with OSCC, predicting relapse with higher sensitivity at various disease stages than routine staging procedures.
Journal ArticleDOI
Liquid biopsies: Potential and challenges.
TL;DR: This work focuses on the most prominent LB markers, circulating tumor cells (CTCs) and circulating tumor‐derived DNA (ctDNA), in the blood of patients with breast, prostate, lung and colorectal cancer, as the four most frequent tumor types in Europe.